Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2985-2995

  Geppert, C I ^a,b   Rummele P ^c   Sarbia, M ^d   Langer, R ^e   Feith, M ^f   Morrison, L ^g   Pestova, E ^h   Schneider Stock, R ^a,b   Hartmann, A ^a,b   Rau, T T ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Friedrich Alexander University Erlangen Nuremberg   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d Department of Pathology and Cytology ^*  (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h Abbott Molecular Inc   (United States)

Author keywords

CDKN2A; ERBB2; Multi colour FISH; MYC; Oesophageal adenocarcinoma; ZNF217

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84902551717     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.238     Document Type: Article

References (70)

1. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D (2010) Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol 21: 1254-1261
2. Akagi T, Ito T, Kato M, Jin Z, Cheng Y, Kan T, Yamamoto G, Olaru A, Kawamata N, Boult J, Soukiasian HJ, Miller CW, Ogawa S, Meltzer SJ, Koeffler HP (2009) Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to oesophageal adenocarcinoma. Int J Cancer 125: 2349-2359
3. Albrecht B, Hausmann M, Zitzelsberger H, Stein H, Siewert JR, Hopt U, Langer R, Höfler H, Werner M, Walch A (2004) Array-based comparative genomic hybridisation for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. J Pathol 203: 780-788. (Pubitemid 38961564
4. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y-K (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697
5. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Patricia C, Paulson TG, Rabinovitch PS, Reid BJ (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22: 106-109. (Pubitemid 29214816
6. Baumann S, Keller G, Pühringer F, Napieralski R, Feith M, Langer R, Höfler H, Stein HJ, Sarbia M (2006) The prognostic impact of O6-Methylguanine-DNA Methyltransferase (MGMT) promotor hypermethylation in oesophageal adenocarcinoma. Int J Cancer 119: 264-268
7. Blot WJ (1994) OEsophageal cancer trends and risk factors. Semin Oncol 21: 403-410
8. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287-1289
9. Bookman Ma (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase ii trial of the gynecologic oncology group. J Clin Oncol 21: 283-290
10. Brankley SM, Fritcher EGB, Smyrk TC, Keeney ME, Campion MB, Voss JS, Clayton AC, Wang KK, Lutzke LS, Kipp BR, Halling KC (2012) Fluorescence in situ hybridisation mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma. Hum Pathol 43: 172-179
11. Brankley SM, Wang KK, Harwood AR, Miller DV, Legator MS, Lutzke LS, Kipp BR, Morrison LE, Halling KC (2006) The development of a fluorescence in situ hybridisation assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diagn 8: 260-267. (Pubitemid 43811251
12. Braun M, Kirsten R, Rupp N, Moch H (2013) Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system. Histol Histopathol. 28: 605-610
13. Brown LM, Devesa SS, Chow W-H (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100: 1184-1187
14. Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: Miniaturized pathology archives for high-Throughput in situ studies. J Pathol 195: 72-79
15. Cavazzola LT, Rosa ARP, da, Schirmer CC, Gurski RR, Telles JPB, Mielke F, Meurer L, Edelweiss MIA, Kruel CDP (2009) Immunohistochemical evaluation for P53 and VEGF (vascular endothelial growth factor) is not prognostic for long term survival in end stage oesophageal adenocarcinoma. Rev Col Bras Cir 36: 24-34
16. Cestari R, Villanacci V, Rossi E, Della Casa D, Missale G, Conio M, Grigolato P, Bassotti G (2007) Fluorescence in situ hybridisation to evaluate dysplasia in Barrett's esophagus: A pilot study. Cancer Lett 251: 278-287. (Pubitemid 46669806
17. Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS (2008) N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res 68: 9654-9662
18. Devesa SS, Blot WJ, Fraumeni JF (1998) Changing patterns in the incidence of oesophageal and gastric carcinoma in the United States. Cancer 83: 2049-2053. (Pubitemid 28525384
19. Dobson L, Conway C, Hanley A, Johnson A, Costello S, O'Grady A, Connolly Y, Magee H, O'Shea D, Jeffers M, Kay E (2010) Image analysis as an adjunct to manual HER-2 immunohistochemical review: A diagnostic tool to standardize interpretation. Histopathology 57: 27-38
20. Esofago D (1991) BARRETT ' S ESOPHAGUS: Epidemiological and clinical results of a multicentric survey. Int J Cancer 48: 364-368
21. Fritcher EB, Brankley S, Kipp B, Voss J (2008) A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridisation for the detection of dysplasia and adenocarcinoma in patients with. Hum Pathol 39: 1128-1135
22. Furrer D, Jacob S, Caron C, Sanschagrin F, Provencher L, Diorio C (2013) Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens. Diagn Pathol 8: 17
23. Gowryshankar A, Nagaraja V, Eslick GD (2014) HER2 status in Barrett's esophagus & oesophageal cancer: A meta analysis. J Gastrointest Oncol 5: 25-35
24. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523-1529
25. Haggitt RC (1994) Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25: 982-993
26. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG (1989) Barrett's esophagus: Development of dysplasia and adenocarcinoma. Gastroenterology 96: 1249-1256. (Pubitemid 19126659
27. Hamilton SR, Aaltonen LA (2000) Pathology and Genetics. Tumours of the Digestive System-WHO-OMS-. WHO: Lyon, France
28. Hamilton SR, Smith RR (1987) The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. Am J Clin Pathol 87: 301-312. (Pubitemid 17046980
29. Heitmiller RF, Sharma RR (1994) Comparison of prevalence and resection rates in patients with oesophageal squamous cell carcinoma and adenocarcinoma. J Thorac Cardiovasc Surg 112: 130-136
30. Hou J, JiangD, Zhang J, Gavine PR, Xu S, Liu Y, Xu C, Huang J, Tan Y, Wang H, Lu Y, Zheng L, Hou Y, Tan L (2014) Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese oesophageal squamous cell carcinoma. Hum Pathol 45: 352-358
31. Huang Q (2010) Biomarkers in Barrett's oesophagus. Biochem Soc Trans 2: 343-347
32. Huang G, Krig S, Kowbel D, Xu H, Hyun B, Volik S, Feuerstein B, Mills GB, Stokoe D, Yaswen P, Collins C (2005) ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 14: 3219-3225. (Pubitemid 41631296
33. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TFE, Bernd H-W, Cogliatti SB, Dierlamm J, Feller AC, Hansmann M-L, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink H-K, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker H-H, Spang R, Loeffler M, Trümper L, Stein H, Siebert R (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419-2430
34. Huober J, Jackisch C, Untch M, Möbus V, Wallwiener D, Kaufmann M, Minkwitz G (2006) Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer. Zentralbl Gynakol 128: 30-37. (Pubitemid 43241853
35. Igaki H, Sasaki H, Kishi T, Sakamoto H, Tachimori Y, Kato H, Watanabe H, Sugimura T, Terada M (1994) Highly frequent homozygous deletion of the p16 gene in oesophageal cancer cell lines. Biochem Biophys Res Commun 203: 1090-1095. (Pubitemid 24304941
36. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stöhr R, Simon R, Sauter G, Leibiger H, Essers L, Weber B, Hermann K, Rosenthal A, Hartmann A, Dahl E (2004) Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 25: 641-649
37. Langer R, Von Rahden BHA, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Höfler H, Sarbia M (2006) Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: A tissue microarray study. J Clin Pathol 59: 631-634. (Pubitemid 43886048
38. Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJP, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z (2012) The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov 2: 638-651
39. Miros M, Kerlin P, Walker N (1991) Only patients with dysplasia progress to adenocarcinoma in Barrett 's oesophagus. Gut 32: 1441-1446
40. Moyes LH, Going JJ (2011) Still waiting for predictive biomarkers in Barrett's oesophagus. J Clin Pathol 64: 742-750
41. Nielsen KV, Ejlertsen B, Møller S, Jensen M-B, Balslev E, Müller S, Knoop A, Mouridsen HT (2012) Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Mol Oncol 6: 88-97
42. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756. (Pubitemid 24153417
43. Ong C-AJ, Lao-Sirieix P, Fitzgerald RC (2010) Biomarkers in Barrett's esophagus and oesophageal adenocarcinoma: Predictors of progression and prognosis. World J Gastroenterol 16: 5669-5681
44. Peitz U, Malfertheiner P (2007) Barrett carcinoma-diagnosis, screening, surveillance, endoscopic treatment, prevention. Z Gastroenterol 45: 1264-1272
45. Peters CJ, Rees JRE, Hardwick RH, Hardwick JS, Vowler SL, Ong CJ, Zhang C, Save V, O'Donovan M, Rassl D, Alderson D, Caldas C, Fitzgerald RC (2010) A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 139: 1995-2004.e15
46. Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of oesophageal adenocarcinoma incidence. J Natl Cancer Inst 97: 142-146. (Pubitemid 40277094
47. Prins MJD, Verhage RJJ, ten Kate FJW, van Hillegersberg R (2012) Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in oesophageal adenocarcinoma. J Gastrointest Surg 16: 956-966
48. Quaroni L, Zhao R, Casson AG (2009) Shining light on Barrett's esophagus. Expert Rev Gastroenterol Hepatol 3: 577-580
49. Rahman MT, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih I-M, Miyazaki K (2012) Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer 118: 2846-2857
50. Rauser S, Weis R, Braselmann H, Feith M, Stein HJ, Langer R, Hutzler P, Hausmann M, Lassmann S, Siewert JR, Höfler H, Werner M, Walch A (2007) Significance of HER2 low-level copy gain in Barrett's cancer: Implications for fluorescence in situ hybridisation testing in tissues. Clin Cancer Res 13: 5115-5123. (Pubitemid 47502079
51. Reid BJ (1991) Barrett's esophagus and oesophageal adenocarcinoma. Gastroenterol Clin North A 20: 817-834
52. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS (2001) Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96: 2839-2848. (Pubitemid 32959522
53. Renouf DJ, Zhai R, Sun B, Xu W, Cheung WY, Heist RS, Kulke MH, Cescon D, Asomaning K, Marshall AL, Li S, Christiani DC, Liu G (2013) Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in oesophageal adenocarcinoma. J Gastroenterol Hepatol 28: 1482-1488
54. Ross JS, McKenna BJ (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investig 19: 554-568. (Pubitemid 32619394
55. Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard M-P, Penault-Llorca F, Nagelmeier I, Schlake W, Höfler H, Kreipe HH (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299-307
56. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van De Vijver M, Viale G (2012) HER2 testing in gastric cancer: A practical approach. Mod Pathol 25(5): 637-650
57. Rygiel AM, van Baal JWPM, Milano F, Wang KK, ten Kate FJ, Fockens P, Rosmolen WD, Bergman JJGHM, Peppelenbosch MP, Krishnadath KK (2007) Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridisation on brush cytology in a Barrett esophagus surveillance population. Cancer 109: 1980-1988. (Pubitemid 46744191
58. Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G (2008) Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 10: R2
59. Schwarz S, Rechenmacher M, Filbeck T, Knuechel R, Blaszyk H, Hartmann a, Brockhoff G (2008) Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. J Clin Pathol 61: 272-277
60. Spechler SJ (1994) Barrett's esophagus. Gastroenterologist 2: 273-284
61. Spechler SJ (2002) Clinical Practice. Barrett's esophagus. N Engl J Med 346: 836-842
62. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J (2005) Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278. (Pubitemid 40309309
63. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ (2007) Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 26: 1465-1477. (Pubitemid 350178802
64. Umar SB, Fleischer De (2008) OEsophageal cancer: Epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol Hepatol 5: 517-526
65. Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of oesophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99: 860-868. (Pubitemid 34575705
66. Wiech T, Nikolopoulos E, Weis R, Langer R, Bartholomé K, Timmer J, Walch AK, Höfler H, Werner M (2009) Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. Lab Invest 89: 385-397
67. Yao H-Q, He S, Wu Y-P, Wang X-C, Han Y-L, Xu X, Cai Y, Wang G-Q, Wang M-R (2008) Application of multicolor fluorescence in situ hybridisation to early diagnosis of oesophageal squamous cell carcinoma. Ai Zheng 27: 1137-1143
68. Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, Sugiyama T, Katai H, Noshiro H, Ushijima T (2014) Integrated analysis of cancerrelated pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer; e-pub ahead or print 9 February 2014; doi:10.1007/s10120-014-0348-0
69. Yoon HH, Shi Q, Sukov WR, Lewis Ma, Sattler Ca, Wiktor AE, Wu T-T, Diasio RB, Jenkins RB, Sinicrope Fa (2012a) Adverse Prognostic Impact of Intratumor Heterogeneous HER2 Gene Amplification in Patients With OEsophageal Adenocarcinoma. J Clin Oncol 30(32): 3932-3938
70. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler Ca, Grothey A, Wu T-T, Diasio RB, Jenkins RB, Sinicrope Fa (2012b) Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in oesophageal adenocarcinomas. Clin Cancer Res 18: 546-554.